An experimental drug that blocks the activation of an immune cell component effectively prevented rejection of heart transplants in mice, according to new research from scientists at Weill Cornell Medicine and Brigham and ...
Dec 13, 2016
0
113
Part of the reason tuberculosis-causing bacteria are so good at colonizing the human body is that they have defenses against the body's immune system. A research team led by a Brown University chemist has developed a new ...
Dec 5, 2016
0
86
Maintaining appropriate levels of proteins within cells largely relies on a cellular component called the proteasome, which degrades unneeded or defective proteins to recycle the components for the eventual assembly of new ...
Aug 16, 2016
0
194
Moffitt Cancer Center will present results from a phase 1 study of selinexor in combination with liposomal doxorubicin and dexamethasone in patients with relapsed and refractory multiple myeloma. The findings will be discussed ...
Jun 6, 2016
0
30
De Bruin carries out chemical-biological research on proteasomes. 'They are a kind of degradation factory that cuts proteins in cells into smaller fragments. It's a highly useful activity: it's a way for cells to clean up ...
May 31, 2016
0
5
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome ...
Apr 28, 2016
0
1
Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.
Sep 2, 2015
0
77
Scientists of the Comprehensive Pneumology Center (CPC) at the Helmholtz Zentrum München have identified a new mechanism which contributes to the development of idiopathic pulmonary fibrosis (IPF). They showed that the pathological ...
Jul 27, 2015
0
9
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) ...
Dec 10, 2014
0
0
Molecular biologists in the School of Medicine at The University of Texas Health Science Center San Antonio have found a novel way to fine-tune the activity of cells' protein-disposing machinery, with potentially cancer-fighting ...
Jul 18, 2013
0
0
